| Trial ID # | NCT02440425 |
| Phase | II |
| Drug Class | Immunotherapy: Checkpoint Inhibitors/PD-1 |
| Drug Name | Pembrolizumab |
| Alternate Drug Names | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 |
| Drugs in Trial | Paclitaxel, Pembrolizumab |
| Eligible Participant | Platinum resistant ovarian cancer |
| Patients Enrolled | 37 |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, PFS, OS, evaluated per RECIST |
| Efficacy | ORR: 51.4% |
| Conclusion | Pembrolizumab+paclitaxel shows improved ORR and PFS compared to historical results with paclitaxel |
| Reference | Wenham RM et al. Phase 2 trial of weekly paclitaxel with pembrolizumab in platinum resistant recurrent ovarian cancer. Intl J Gynecol Cancer (2018) 28 (Suppl 2) 1-1258 Combinations Will Lead the Way in Immunotherapy for Ovarian Cancer, Onc LIve SGO WInter Meeting Conference Coverage, 2/10/2020 |